AdAlta is a clinical stage drug discovery and development company leveraging its i-body (single domain antibody) platform to create novel protein therapeutics. The company has a specific focus on diseases where GPCRs are implicated, and on antibody, Fc-fusion and CAR-T/NK formats. Lead asset AD-214 is a first in class anti-fibrotic that has completed Phase I and is being prepared for Phase II studies in IPF. The company also has collaborations with GE Healthcare (PET imaging in immuno-oncology) and Carina Biotech (CAR-T).